title: [Update on current care guidelines: ovarian cancer].
abstract: Ovarian cancer is the most lethal gynaecological cancer. It appears that seemingly ovarian or primary peritoneal carcinomas, in fact, originate from fimbriae. BRCA1/2 mutation carriers are recommended for the removal of ovaries and fimbriae, to reduce the risk of cancer. Treatment of epithelial ovarian cancer is based on the combination of surgery and chemotherapy. The residual tumour volume at the primary operation is the most important predictive factor of survival. The best response at the primary treatment is observed with combination chemotherapy with taxane and platinum. Adding bevacitzumab to first line chemotherapy may improve survival.
authors: Gynekologiyhdistyksen asettama työryhmä.
authors: Arto
authors: A
authors: Leminen
authors: Annika
authors: A
authors: Auranen
authors: Ralf
authors: R
authors: Bützow
authors: Sakari
authors: S
authors: Hietanen
authors: Marja
authors: M
authors: Komulainen
authors: Tapio
authors: T
authors: Kuoppala
authors: Johanna
authors: J
authors: Mäenpää
authors: Ulla
authors: U
authors: Puistola
authors: Maarit
authors: M
authors: Vuento
authors: Piia
authors: P
authors: Vuorela
authors: Merja
authors: M
authors: Yliskoski
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D017410:Practice Guidelines as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000068258:Bevacizumab; D002945:Cisplatin